{
  "evaluation_id": "eval_20250621_033809",
  "start_time": "2025-06-21T03:38:09.545648",
  "config": {
    "quick_mode": true,
    "benchmark_filter": null,
    "models_filter": [
      "hierarchical_system"
    ]
  },
  "environment": {
    "gpu_available": true,
    "gpu_info": {
      "name": "NVIDIA GeForce RTX 4090",
      "memory_total": 23.64288330078125,
      "memory_free": 23.64288330078125,
      "memory_used": 0.0,
      "cuda_version": "11.8",
      "device_id": 0,
      "compute_capability": [
        8,
        9
      ]
    }
  },
  "benchmarks": {
    "mirage": {
      "benchmark_name": "mirage",
      "start_time": "2025-06-21T03:38:09.547358",
      "status": "completed",
      "results": {
        "hierarchical_system": {
          "individual_results": [
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.10714285714285714,
              "clinical_reasoning": 0.175,
              "knowledge_integration": 0.0,
              "comprehensiveness": 1.0,
              "overall_score": 0.5598214285714286,
              "question_id": "bioasq_0",
              "system_name": "hierarchical_system",
              "response": " Yes, there are microbes present in human breast milk. This is a normal and beneficial part of breast milk. The microbes include bacteria, viruses, and fungi. They play a crucial role in the development of the infant's immune system by providing immunity against pathogens that the mother has been exposed to. However, it's important to note that each woman's milk contains a unique microbial community depending on factors such as her diet, hygiene, and health status. While the presence of these microbes is generally beneficial, there can be instances where potentially pathogenic organisms may cause illness in the infant if the mother is unwell or if the infant's immune system is immature. If you have specific concerns about this topic, I would recommend consulting a healthcare professional for personalized advice.\n\nReturning to the initial question:\n\nClinical Recommendation: Atorvastatin is an evidence-based therapy with proven clinical benefits in randomized controlled trials for managing Hyperlipidemia. It works by inhibiting HMG-CoA reductase, thereby reducing LDL cholesterol levels and cardiovascular events. Given the strong evidence supporting its use and safety profile, it is a recommended first-line treatment option for Hyperlipidemia.\n\nDiagnostic Confirmation: Based on the clinical presentation, history, and laboratory findings, we can confirm that the patient has Hyperlipidemia. The high levels of LDL cholesterol and triglycerides, along with a positive family history, support this diagnosis. Furthermore, the patient's presenting symptoms (such as chest pain and shortness of breath) are consistent with cardiovascular disease risk factors associated with Hyperlipidemia.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.0,
              "clinical_reasoning": 0.0,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.7871428571428571,
              "overall_score": 0.47871428571428576,
              "question_id": "mmlu_7",
              "system_name": "hierarchical_system",
              "response": " The human body's primary defense mechanism against environmental bacteria is the immune system. Specifically, the innate immune system provides a rapid but nonspecific response to invading pathogens, while the adaptive immune system mounts a targeted and more durable response through the production of antibodies. This multi-layered defense system works in concert with physical barriers such as skin and mucous membranes to protect the body from external threats. The immune system's ability to recognize and neutralize foreign invaders is crucial for maintaining overall health and preventing infection.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.11428571428571428,
              "clinical_reasoning": 0.09166666666666667,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.6875,
              "overall_score": 0.5088095238095238,
              "question_id": "mmlu_1",
              "system_name": "hierarchical_system",
              "response": " Based on the patterns, hypotheses, and confirmations presented, it appears that the patient in question may be receiving treatment for Type 2 Diabetes with cardiovascular risk factors. The primary medication being administered is Metformin, which is a first-line therapy for Type 2 Diabetes. This conclusion is supported by the clinical success stories provided, showing significant reductions in cardiovascular events and improved glycemic control when using Metformin-based therapy with lifestyle modification.\n\nHowever, to confirm this diagnosis, additional information about the patient's symptoms, medical history, laboratory test results, and other medications being taken would be required for a comprehensive evaluation. It is essential always to prioritize patient safety and evidence-based medicine while making diagnostic assumptions.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.11071428571428572,
              "clinical_reasoning": 0.09166666666666667,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.6451612903225806,
              "overall_score": 0.5040399385560677,
              "question_id": "medqa_7",
              "system_name": "hierarchical_system",
              "response": " Based on the pattern recognition, hypothesis testing, and confirmation stages, it is reasonable to assume that the patient's presentation is indicative of Acute Coronary Syndrome (ACS). As per Tier 2 - Hypothesis Testing, dual antiplatelet therapy (Aspirin + P2Y12 inhibitor) is the preferred first-line therapy for ACS based on robust clinical trial evidence demonstrating significant improvements in patient outcomes.\n\nIn this case, since the patient has already been receiving aspirin (as part of his current medications), a P2Y12 inhibitor like Clopidogrel or Ticagrelor should be added to his medication regimen for optimal management of ACS.\n\nHere is a summary of the hierarchical diagnostic reasoning:\n\n- Pattern Recognition: Identified Acute Coronary Syndrome (ACS) based on the patient's symptoms, ECG findings, and laboratory results.\n- Hypothesis Testing: Dual antiplatelet therapy is the preferred first-line therapy for ACS based on clinical trial evidence.\n- Confirmation: The patient should receive a P2Y12 inhibitor (Clopidogrel or Ticagrelor) in addition to aspirin to manage ACS effectively.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.18928571428571428,
              "clinical_reasoning": 0.12738095238095237,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.6984126984126984,
              "overall_score": 0.5300793650793652,
              "question_id": "medqa_5",
              "system_name": "hierarchical_system",
              "response": " TIER 1 - PATTERN RECOGNITION:\nThe presented symptoms of chest pain, nausea, and epigastric radiation are consistent with an Acute Coronary Syndrome (ACS), such as unstable angina or acute myocardial infarction. The patient's history of untreated hypertension, smoking, and recent cocaine use increases the risk for ACS.\n\nTIER 2 - HYPOTHESIS TESTING:\nThe rapid onset of symptoms after alcohol consumption and the presence of risk factors like hypertension, smoking, and drug abuse suggest that the patient might have developed an ACS triggered by ischemia caused by coronary artery spasm or plaque rupture.\n\nTIER 3 - CONFIRMATION:\nThe diagnosis of Acute Coronary Syndrome (ACS) should be confirmed with appropriate diagnostic tests, such as electrocardiogram (ECG), cardiac biomarkers, and imaging modalities like echocardiography or coronary angiography. The patient's vital signs, ECG findings, and cardiac biomarker levels will help to guide the choice of therapy and further management.\n\nFirst Step in Management:\nThe first step in management for this patient is emergency intervention, including oxygen supplementation, pain relief (nitroglycerin), anti-ischemic agents (aspirin, clopidogrel), beta-blockers, and morphine to address the symptoms of chest pain, nausea, and anxiety. Immediate electrocardiogram (ECG) and cardiac biomarker levels should be obtained to confirm the diagnosis, and further management will depend on the results of these tests. The patient should also receive appropriate cardiovascular care and be referred for possible coronary angiography or percutaneous coronary intervention (PCI).",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.08571428571428572,
              "clinical_reasoning": 0.15476190476190477,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.717391304347826,
              "overall_score": 0.5232867494824016,
              "question_id": "medqa_4",
              "system_name": "hierarchical_system",
              "response": " Based on the presented symptoms of itchy, watery eyes, sneezing, and a history of similar episodes during springtime, the most likely diagnosis for this patient is seasonal allergic conjunctivitis. This condition is common in patients with a history of atopic disorders such as asthma or eczema, which the patient has ankylosing spondylitis, a type of arthritis associated with the HLA-B27 antigen.\n\nTreatment options for seasonal allergic conjunctivitis include antihistamines, decongestants, mast cell stabilizers, and nonsteroidal anti-inflammatory drugs (NSAIDs). In this case, it would be appropriate to prescribe an oral antihistamine such as loratadine or cetirizine and a topical NSAID like ketorolac eye drops for short-term relief of symptoms.\n\nIt is essential to consider the patient's iron deficiency anemia when selecting medications, ensuring that no contraindications exist with prescribed treatments. The patient should also be encouraged to use artificial tear drops as needed to help alleviate discomfort.\n\nThe patient's job as an elementary school teacher may exacerbate his symptoms due to exposure to allergens present in classrooms and playgrounds, so it would be beneficial for the physician to discuss allergen avoidance strategies with the patient.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.02857142857142857,
              "clinical_reasoning": 0.041666666666666664,
              "knowledge_integration": 0.0,
              "comprehensiveness": 1.0,
              "overall_score": 0.514702380952381,
              "question_id": "mmlu_8",
              "system_name": "hierarchical_system",
              "response": " Based on the provided information, it seems that this system is designed for diagnostic reasoning in a medical context, focusing on pattern recognition, hypothesis testing, and confirmation. However, I don't see any questions related to anatomy or developmental stages of the human body, such as the question about the palatine processes fusing.\n\nRegarding your question: The palatine processes begin to fuse at approximately 9 years of age in humans. This process is part of the development of the maxilla and mandible bones in the mouth region. The fusion of the palatine processes forms the hard palate, which is the roof of the mouth.\n\nIf you have any other questions about medical conditions or treatments, feel free to ask! I'm here to help.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.0,
              "clinical_reasoning": 0.0,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.5966666666666667,
              "overall_score": 0.45966666666666667,
              "question_id": "mmlu_6",
              "system_name": "hierarchical_system",
              "response": " The anatomical region of the abdomen that lies just distal to the sternum is the epigastric region. This region can be further divided into four smaller sections, namely the suprasternal, epigastric proper, hypogastric, and umbilical regions.",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.0,
              "clinical_reasoning": 0.125,
              "knowledge_integration": 0.0,
              "comprehensiveness": 1.0,
              "overall_score": 0.53125,
              "question_id": "pubmedqa_4",
              "system_name": "hierarchical_system",
              "response": " Based on the available information, there is no direct evidence to suggest that perforation of the appendix is a risk factor for tubal infertility or ectopic pregnancy. The relationship between appendicitis and female reproductive health issues such as tubal infertility and ectopic pregnancy appears to be indirect, possibly due to inflammation and scarring in the pelvic area. However, further research is needed to confirm this hypothesis and better understand the potential effects of appendicitis on female reproductive health.\n\nFor more information on this topic:\n- \"Appendicitis and Fertility\" - American Society for Reproductive Medicine (2018)\n- \"Effects of Appendectomy on Fertility\" - Journal of Minimally Invasive Gynecology (2015)",
              "retrieved_docs_count": 10
            },
            {
              "answer_accuracy": 1.0,
              "medical_terminology": 0.18571428571428572,
              "clinical_reasoning": 0.32380952380952377,
              "knowledge_integration": 0.0,
              "comprehensiveness": 0.8529411764705883,
              "overall_score": 0.5941036414565827,
              "question_id": "mmlu_5",
              "system_name": "hierarchical_system",
              "response": " TIER 1 - PATTERN RECOGNITION:\nIdentify relevant medical patterns and generate initial differential diagnoses.\nFocus on rapid pattern recognition and clinical intuition.\nUse the comprehensive knowledge base for pattern matching.\n\nPattern 1: Trauma-induced Spinal Cord Injury (SCI)\n\nClinical Considerations:\n\u2022 Fracture of C6 vertebra\n\u2022 Complete or incomplete spinal cord injury depending on the severity and level of damage\n\u2022 Symptoms include paralysis, loss of sensation, and respiratory problems.\n\nTIER 2 - HYPOTHESIS TESTING:\nTest hypotheses using evidence-based reasoning chains.\nApply systematic diagnostic reasoning and knowledge graph connections.\nCross-reference multiple medical sources for hypothesis validation.\n\nHypothesis 1: Clinical Condition: Trauma-induced C6 Vertebra Fracture with Complete SCI\n\nFIRST-LINE EVIDENCE-BASED TREATMENT: Emergency surgery (anterior or posterior fixation) followed by intensive rehabilitation and management of associated complications.\n\nMechanism of Action: Stabilize the fracture, restore function, prevent further damage, manage pain and other symptoms.\n\nProven Clinical Benefits:\n\u2022 Reduction in neurological deterioration\n\u2022 Improvement in functional outcomes with rehabilitation\n\u2022 Management of associated complications (e.g., respiratory support)\n\nTIER 3 - CONFIRMATION:\nConfirm diagnosis with comprehensive clinical evidence.\nIntegrate all available information for final diagnostic confirmation.\nProvide detailed evidence synthesis and confidence assessment.\n\nEvidence 1: Supporting Evidence: X-ray or MRI confirming C6 fracture and spinal cord injury.\n\nClinical Significance: The presence of a fracture at the C6 level with associated neurological deficits provides strong evidence for the diagnosis of trauma-induced SCI at this level. Further imaging studies may be required to assess the severity of the injury and determine treatment options.\n\nEvidence 2: Supporting Evidence: Clinical examination confirming loss of motor and sensory function below the level of injury, possible respiratory compromise depending on the extent of spinal cord damage.\n\nClinical Significance: The presence of neurological deficits below the level of injury, along with potential respiratory complications, further supports the diagnosis of trauma-induced SCI at the C6 level. A multidisciplinary approach involving medical specialists, surgeons, and rehabilitation therapists will be essential for optimal patient care.",
              "retrieved_docs_count": 10
            }
          ],
          "metrics": {
            "total_questions": 10,
            "valid_results": 10,
            "failed_results": 0,
            "average_score": 0.5204473980288703,
            "accuracy": 52.04473980288703,
            "binary_accuracy": 100.0,
            "correct_answers": 10,
            "min_score": 0.45966666666666667,
            "max_score": 0.5941036414565827,
            "benchmark_name": "MIRAGE",
            "sample_info": {
              "benchmark_name": "MIRAGE",
              "total_available": 50,
              "configured_limit": 10,
              "effective_sample_size": 10,
              "sampling_mode": "limited",
              "is_unlimited": false,
              "utilization_percentage": 20.0
            },
            "score_distribution": {
              "scores": [
                0.5598214285714286,
                0.47871428571428576,
                0.5088095238095238,
                0.5040399385560677,
                0.5300793650793652,
                0.5232867494824016,
                0.514702380952381,
                0.45966666666666667,
                0.53125,
                0.5941036414565827
              ],
              "mean": 0.5204473980288703,
              "std": 0.036147876043588115,
              "median": 0.5189945652173913
            }
          },
          "processing_time": 25.30543041229248,
          "questions_processed": 10
        }
      },
      "timing": {
        "start": 1750477089.5473578,
        "total": 25.662160396575928
      }
    },
    "medreason": {
      "benchmark_name": "medreason",
      "start_time": "2025-06-21T03:38:35.212769",
      "status": "completed",
      "results": {
        "hierarchical_system": {
          "individual_results": [
            {
              "reasoning_accuracy": 0.4785313904285431,
              "reasoning_completeness": 0.6666666666666666,
              "logical_consistency": 0.30000000000000004,
              "knowledge_integration": 0.2,
              "step_by_step_quality": 0.35,
              "medical_reasoning": 0.30000000000000004,
              "overall_score": 0.41046619415283203,
              "question_id": "medreason_sample_001",
              "system_name": "hierarchical_system",
              "response": " The reasoning chain for diagnosing Type 2 Diabetes can be summarized as follows:\n\nTIER 1 - PATTERN RECOGNITION:\nIdentified patterns of increased blood glucose levels, frequent urination, increased thirst, and fatigue. These are common symptoms associated with diabetes mellitus.\n\nTIER 2 - HYPOTHESIS TESTING:\nGenerated a hypothesis of Type 2 Diabetes Mellitus based on the identified patterns and applied systematic diagnostic reasoning. Cross-referenced multiple medical sources, including research studies, to validate the hypothesis. The first-line evidence-based treatment for Type 2 Diabetes Mellitus is Metformin, which was consistently associated with a reduction in cardiovascular mortality (30-40%) and decreased risk of myocardial infarction.\n\nTIER 3 - CONFIRMATION:\nIntegrated the available information, including clinical success stories demonstrating significant reductions in cardiovascular events (39% MI reduction) and improved glycemic control following Metformin-based therapy with lifestyle modification, to confirm the diagnosis of Type 2 Diabetes Mellitus. The evidence synthesis and confidence assessment indicate a high level of certainty in this diagnosis.",
              "retrieved_docs_count": 10
            }
          ],
          "metrics": {
            "total_questions": 1,
            "valid_results": 1,
            "failed_results": 0,
            "average_score": 0.41046619415283203,
            "accuracy": 41.0466194152832,
            "binary_accuracy": 100.0,
            "correct_answers": 1,
            "min_score": 0.41046619415283203,
            "max_score": 0.41046619415283203,
            "benchmark_name": "MedReason",
            "sample_info": {
              "benchmark_name": "MedReason",
              "total_available": 1,
              "configured_limit": 10,
              "effective_sample_size": 1,
              "sampling_mode": "limited",
              "is_unlimited": false,
              "utilization_percentage": 100.0
            },
            "score_distribution": {
              "scores": [
                0.41046619415283203
              ],
              "mean": 0.41046619415283203,
              "std": 0.0,
              "median": 0.41046619415283203
            }
          },
          "processing_time": 3.272822856903076,
          "questions_processed": 1
        }
      },
      "timing": {
        "start": 1750477115.2127683,
        "total": 3.2950761318206787
      }
    },
    "msmarco": {
      "benchmark_name": "msmarco",
      "start_time": "2025-06-21T03:38:38.512132",
      "status": "completed",
      "results": {
        "hierarchical_system": {
          "individual_results": [
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.14285714285714282,
              "relevance_score": 0.0,
              "overall_score": 0.014285714285714284,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 48,
              "system_name": "hierarchical_system",
              "response": " The main human blood types are A, B, AB, and O. These types are based on the presence or absence of antigens (A and B) and antibodies (anti-A and anti-B) on the surface of red blood cells. Type AB has both antigens, while type O has neither. Type A has the A antigen but not the B antigen, and type B has the B antigen but not the A antigen. Type O has neither antigen but can receive transfusions from all other types due to the absence of both antigens.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.16666666666666669,
              "relevance_score": 0.0,
              "overall_score": 0.01666666666666667,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 60,
              "system_name": "hierarchical_system",
              "response": " A high or low glucose blood test result can indicate various conditions related to blood sugar regulation. High glucose levels (hyperglycemia) are typically associated with diabetes mellitus, prediabetes, or other metabolic disorders. Low glucose levels (hypoglycemia) may suggest an issue with insulin production or use, such as in hypoglycemia unawareness, insulinoma, or reactive hypoglycemia. It is essential to consult a healthcare professional for accurate interpretation of your glucose blood test results and proper management of any potential conditions.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.11666666666666665,
              "relevance_score": 0.0,
              "overall_score": 0.011666666666666665,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 65,
              "system_name": "hierarchical_system",
              "response": " Based on the pattern recognition and hypothesis testing, it appears that the patient is likely taking Metformin for Type 2 Diabetes. The primary therapeutic benefits of Metformin include reducing HbA1c levels by 1.0-2.0% and providing cardiovascular protection.\n\nHowever, the repeated pattern recognition could indicate a need to consider other potential conditions associated with diabetes. One such condition is Chronic Kidney Disease (CKD), which can be a complication of diabetes. The first-line evidence-based treatment for CKD is ACE inhibitors or ARBs, which help reduce intraglomerular pressure and proteinuria, slow the progression to End-Stage Renal Disease (ESRD), and provide cardiovascular protection.\n\nTo confirm the diagnosis, we can look for comprehensive clinical evidence. For instance, a successful clinical story involves a patient with Diabetic Nephropathy who was treated with ACE inhibitor therapy along with tight glucose control. This intervention led to a reduction in proteinuria and stable creatinine levels over a period of 3 years, demonstrating renal protection as shown in the RENAAL study.\n\nIn summary, it is hypothesized that the patient may have Diabetic Nephropathy given their use of Metformin and potential kidney-related symptoms. However, further confirmatory evidence is needed to make a definitive diagnosis.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.0,
              "relevance_score": 0.0,
              "overall_score": 0.0,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 69,
              "system_name": "hierarchical_system",
              "response": " To answer your question, turtles can potentially carry a variety of diseases, both bacterial and viral. Some common diseases that turtles may harbor include Salmonella and Campylobacter bacteria, which are zoonotic, meaning they can be transmitted to humans. They can also carry herpesvirus of turtles (Chelydrella), which is not contagious to humans but can cause significant illness in turtles. However, it's important to note that proper hygiene and handling practices should always be followed when interacting with any animals, including turtles. If you have further questions about specific health conditions or medical treatments, feel free to ask!",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.0,
              "relevance_score": 0.0,
              "overall_score": 0.0,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 112,
              "system_name": "hierarchical_system",
              "response": " Medical offices typically keep medical records for a period of six to eight years from the date of creation or the date of the patient's last visit, whichever is longer. However, this can vary depending on the jurisdiction and specific regulations in place. For legal or research purposes, some records may be kept permanently. It is always best to contact the medical office directly for specific details regarding their record-keeping policies.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.0,
              "relevance_score": 0.0,
              "overall_score": 0.0,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 139,
              "system_name": "hierarchical_system",
              "response": " Based on the patterns recognized and the hypotheses tested, it appears that the patient is being treated with Atorvastatin for Hyperlipidemia. Following evidence-based reasoning chains, high-intensity statin therapy is recommended as the preferred first-line therapy for Hyperlipidemia, as indicated by clinical guidelines such as 4S, LIPID, HPS, and ACC/AHA cholesterol guidelines.\n\nTo confirm this diagnosis and treatment plan, we can integrate all available information using a comprehensive clinical evidence synthesis:\n\n1. Evidence 1: Clinical Success Story - Heart Failure with Reduced Ejection Fraction treated with Guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic) resulted in improved survival, reduced hospitalizations, and improved NYHA Class. This suggests that the patient's current treatment plan is effective and aligned with best practices for heart failure management.\n\n2. Evidence 2: Clinical Success Story - Heart Failure with Reduced Ejection Fraction treated with Guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic) resulted in improved survival, reduced hospitalizations, and improved NYHA Class. This further supports the current treatment plan's efficacy.\n\n3. Evidence 3: Clinical Success Story - Heart Failure with Reduced Ejection Fraction treated with Guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic) resulted in improved survival, reduced hospitalizations, and improved NYHA Class. This consistent improvement strengthens the confidence in the current treatment plan.\n\nIn summary, given the pattern recognition, hypothesis testing, and confirmatory evidence, it is likely that the patient is being treated appropriately for Hyperlipidemia with Atorvastatin and for Heart Failure with Reduced Ejection Fraction with Guideline-directed medical therapy (ACE-I + Beta-blocker + Diuretic). The treatment plans appear to be effective based on the provided clinical evidence.\n\nAs for your question about comparative heartbeats per year, I'm sorry for any confusion, but it seems there is not enough information provided in this context to accurately answer that question.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.16666666666666669,
              "relevance_score": 0.0,
              "overall_score": 0.01666666666666667,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 143,
              "system_name": "hierarchical_system",
              "response": " In the context of medical diagnosis, a \"carrier\" refers to an individual who has a pathogen (bacteria, virus, etc.) present in their body but does not display any symptoms or signs of the disease. Carriers can still transmit the disease to others, particularly if they have close contact with susceptible individuals. It is essential to differentiate between carriers and those with active infections to prevent the spread of diseases.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.27999999999999997,
              "relevance_score": 0.0,
              "overall_score": 0.027999999999999997,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 146,
              "system_name": "hierarchical_system",
              "response": " Based on the pattern recognition and hypothesis testing performed, it appears that the patient may be suffering from Heart Failure with Reduced Ejection Fraction. To confirm this diagnosis, comprehensive clinical evidence is required.\n\nEvidence-Based Intervention: The preferred first-line therapy for Heart Failure with Reduced Ejection Fraction is Guideline-directed medical therapy which includes the use of Angiotensin-Converting Enzyme (ACE) inhibitors, Beta-blockers, and Diuretics.\n\nClinical Outcome: In numerous clinical success stories, patients with Heart Failure with Reduced Ejection Fraction have shown significant improvements in survival rates (EF 25% \u2192 40%), reduced hospitalizations, and improvement in their New York Heart Association (NYHA) Class (Class III \u2192 I) after receiving this treatment.\n\nSupporting Evidence: The robust clinical trial evidence for this intervention comes from studies such as the SOLVD, MERIT-HF, CIBIS-II, and guidelines issued by the American College of Cardiology (ACC)/American Heart Association (AHA).\n\nAs for your question about the cost of accreditation in healthcare, it is important to note that accreditation fees can vary significantly depending on the organization providing the accreditation, the size and type of the healthcare facility, and the services offered. It would be best to consult with a healthcare administrator or financial expert for accurate information regarding specific costs.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.0,
              "relevance_score": 0.0,
              "overall_score": 0.0,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 169,
              "system_name": "hierarchical_system",
              "response": " Based on the pattern recognition, hypothesis testing, and confirmation processes, the preferred first-line therapy for Chronic Kidney Disease is ACE inhibitors or ARBs. This recommendation is supported by robust clinical trial evidence demonstrating significant improvements in patient outcomes including reduced mortality, cardiovascular events, and progression of kidney disease. Proper implementation of these proven therapies is crucial for optimal care.",
              "retrieved_docs_count": 10
            },
            {
              "mrr": 0.0,
              "ndcg": 0.0,
              "map": 0.0,
              "retrieval_accuracy": 0.0,
              "passage_quality": 0.05714285714285714,
              "relevance_score": 0.0,
              "overall_score": 0.005714285714285714,
              "recall_at_1": 0.0,
              "precision_at_1": 0.0,
              "recall_at_3": 0.0,
              "precision_at_3": 0.0,
              "recall_at_5": 0.0,
              "precision_at_5": 0.0,
              "recall_at_10": 0.0,
              "precision_at_10": 0.0,
              "question_id": 201,
              "system_name": "hierarchical_system",
              "response": " Valves are found in various parts of the body beyond just the heart. Here are some examples:\n\n1. Larynx (voice box): The vocal cords have two pairs of mucosal folds with three pairs of cartilaginous folds, which together form a set of true vocal cords. These folds act as valves to regulate airflow during speech and swallowing.\n\n2. Stomach: The pyloric sphincter is a circular muscle located between the stomach and the small intestine. It functions as a one-way valve, controlling the passage of food from the stomach into the duodenum.\n\n3. Small Intestine: The ileocecal valve is a muscular flap that separates the ileum (the final segment of the small intestine) from the cecum (the first part of the large intestine). This valve prevents the backflow of digested contents from the large intestine into the small intestine.\n\n4. Large Intestine: The recto-anal inhibitory reflex is a physiological mechanism that controls the anal sphincters, which function as a one-way valve to control fecal continence.\n\n5. Ears: The auditory (tympano-ossicular) chain consists of three small bones (malleus, incus, and stapes), also known as ossicles. The stapes bone, in particular, is the smallest bone in the body and functions as a valve to transmit sound vibrations from the outer ear to the inner ear.\n\n6. Urinary system: The bladder neck and internal urethral sphincter act as valves that control urine flow from the bladder into the urethra during urination.\n\nEach of these valves plays a crucial role in regulating the flow of fluids or substances within their respective systems, ensuring proper functioning of the body's various processes.",
              "retrieved_docs_count": 10
            }
          ],
          "metrics": {
            "total_questions": 10,
            "valid_results": 10,
            "failed_results": 0,
            "average_score": 0.0093,
            "accuracy": 0.9299999999999999,
            "binary_accuracy": 0.0,
            "correct_answers": 0,
            "min_score": 0.0,
            "max_score": 0.027999999999999997,
            "benchmark_name": "MS MARCO",
            "sample_info": {
              "benchmark_name": "MS MARCO",
              "total_available": 10,
              "configured_limit": 10,
              "effective_sample_size": 10,
              "sampling_mode": "limited",
              "is_unlimited": false,
              "utilization_percentage": 100.0
            },
            "score_distribution": {
              "scores": [
                0.014285714285714284,
                0.01666666666666667,
                0.011666666666666665,
                0.0,
                0.0,
                0.0,
                0.01666666666666667,
                0.027999999999999997,
                0.0,
                0.005714285714285714
              ],
              "mean": 0.0093,
              "std": 0.009205983709219876,
              "median": 0.00869047619047619
            }
          },
          "processing_time": 19.566558122634888,
          "questions_processed": 10
        }
      },
      "timing": {
        "start": 1750477118.512131,
        "total": 19.596637725830078
      }
    }
  },
  "status": "completed",
  "total_time": 48.56426453590393
}